WASHINGTON (Legal Newsline) — The Federal Trade Commission announced July 11 that it has approved Quantic Regulatory Services LLC as a monitor in the agency’s case against Endo Pharmaceutics Inc. for alleged antitrust violations.
Endo Pharmaceuticals had allegedly used pay-for-delay tactics to block consumer access to lower-cost generic versions of Opana ER and Lipoderm. Endo and its subsidiaries were banned from entering anti-competitive patent settlements after an FTC order entered by the Federal District Court for the Northern District of California on Feb. 2.
The order allows Endo to enter supply agreements related to patent settlements only if they meet certain standards. As part of the order, the FTC would appoint a monitor to evaluate whether Endo was complying with the order’s requirements.
The FTC voted 2-0 to approve the appointment of the monitor. Susan Huber of the Bureau of Competition is the staff contact for the case.